Bittl John A, Feldman Robert L
Ocala Heart and Vascular Institute, Munroe Regional Medical Center, Ocala, Florida, USA.
Catheter Cardiovasc Interv. 2005 Nov;66(3):309-15. doi: 10.1002/ccd.20519.
Vascular access failure is the greatest limitation of successful hemodialysis, but the factors associated with long-term patency have not been fully elucidated. Outcomes in a consecutive series of 294 thrombosed or failing accesses [128 fistulas (43.5%) and 166 grafts (56.5%) in 179 patients] were analyzed with life table and multivariable Cox proportional hazards analysis. Initial success was achieved in 275 of 294 accesses (95.6%). The median patency after intervention was 206 days (interquartile range, 79-457 days). Fistulas had longer median patency after intervention than grafts (286 vs. 170 days). Nonthrombosed accesses had longer median patency than thrombosed accesses (238 vs. 136 days), but thrombosed fistulas had similar median patency as thrombosed grafts (140 vs. 136 days). The selective use of stents as a bailout for failed balloon dilatation did not significantly reduce long-term patency (196 days for stented accesses vs. 210 days for unstented accesses). Long-term patency was inversely related to final access pressure, but access patency was not related to the presence of central venous occlusions, graft age, patient age, sex, or diabetes. Catheter-based intervention of thrombosed and failing dialysis accesses significantly prolongs patency and usefulness of dialysis accesses. The expanding use of fistulas, improved detection of early access failure, and selective use of bailout stents should enhance long-term access patency.
血管通路失败是成功进行血液透析的最大限制因素,但与长期通畅相关的因素尚未完全阐明。对连续294例血栓形成或功能不良的血管通路(179例患者中有128条动静脉内瘘(43.5%)和166条移植物血管通路(56.5%))的结果进行了生存表分析和多变量Cox比例风险分析。294条血管通路中有275条(95.6%)首次干预成功。干预后的中位通畅时间为206天(四分位间距,79 - 457天)。干预后,动静脉内瘘的中位通畅时间比移植物血管通路更长(286天对170天)。未形成血栓的血管通路的中位通畅时间比形成血栓的血管通路更长(238天对136天),但形成血栓的动静脉内瘘与形成血栓的移植物血管通路的中位通畅时间相似(140天对136天)。作为球囊扩张失败后的补救措施而选择性使用支架,并未显著降低长期通畅率(置入支架的血管通路为196天,未置入支架的血管通路为210天)。长期通畅率与最终血管通路压力呈负相关,但血管通路通畅率与中心静脉闭塞的存在、移植物使用时长、患者年龄、性别或糖尿病无关。基于导管的血栓形成和功能不良的透析血管通路干预可显著延长透析血管通路的通畅时间和使用寿命。扩大动静脉内瘘的使用、改善早期血管通路失败的检测以及选择性使用补救支架应可提高长期血管通路通畅率。